Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946456 | 0.94 | HSD17B10 (0.36) | TAS1R3TAS1R1HPGDABCB1ALDH1A1 | |
| SCHEMBL9903289 | 0.86 | NPC1 (0.35) | HPGDABCB1ALDH1A1MAPT | |
| SCHEMBL19946432 | 0.84 | ABCB1 (0.34) | TAS1R3TAS1R1HPGDABCB1ALDH1A1 | |
| SCHEMBL19946426 | 0.80 | TAS1R3 (0.37) | TAS1R3TAS1R1HPGDABCB1 | |
| SCHEMBL2683271 | 0.80 | TAS1R3 (0.37) | TAS1R3TAS1R1HPGDABCB1 | |
| SCHEMBL22363198 | 0.79 | ABCB1 (0.50) | TAS1R3TAS1R1ABCB1 | |
| SCHEMBL18625531 | 0.79 | ABCB1 (0.50) | TAS1R3TAS1R1ABCB1 | |
| SCHEMBL22363208 | 0.78 | ABCB1 (0.43) | TAS1R3TAS1R1ABCB1 | |
| SCHEMBL19946414 | 0.78 | ABCB1 (0.43) | TAS1R3TAS1R1ABCB1 | |
| SCHEMBL22363211 | 0.77 | PRSS1 (0.43) | TAS1R3TAS1R1HPGDABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | claimed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | TAS1R3 3889/4885TAS1R1 4166/4885HPGD 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.